Page last updated: 2024-11-13

indapamide, perindopril drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indapamide, perindopril drug combination: an antihypertensive [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56841493
MeSH IDM0539815

Synonyms (12)

Synonym
indapamide, perindopril drug combination
coversyl plus
S900005380
coversum combi
indapamide / perindopril
predonium
perindopril-indapamide
noriplel
biprel
noliprel
prelectal
bipreterax

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43
" The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Dosage could be increased to 10/2."( Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
Pella, D, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (23.33)29.6817
2010's43 (71.67)24.3611
2020's3 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.91 (24.57)
Research Supply Index4.49 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index59.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (41.94%)5.53%
Reviews10 (16.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational5 (8.06%)0.25%
Other21 (33.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension [NCT03747978]Phase 430 participants (Actual)Interventional2016-10-01Completed
"Multinational Observational Uncontrolled Open Programme The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy" [NCT03722524]1,247 participants (Actual)Observational2018-10-01Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation [NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India [NCT05683301]Phase 41,968 participants (Anticipated)Interventional2022-08-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03722524 (5) [back to overview]Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline

Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline

The assessment of the target office BP levels (SBP <140 mm Hg and DBP <90 mm Hg) was performed in accordance with ESC Guidelines for the management of arterial hypertension (2013) (NCT03722524)
Timeframe: Baseline, 3 months

Interventionpercentage of patients (Number)
Patients With Arterial Hypertension93.38

[back to top]

The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.

Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension14.34

[back to top]

The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the SF-36 survey Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension23.57

[back to top]

The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension13.64

[back to top]

The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline

Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded. (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension33.47

[back to top]